Biomarkers in bladder cancer: Translational and clinical implications

Liang Cheng, Darrell D. Davison, Julia Adams, Antonio Lopez-Beltran, Lisha Wang, Rodolfo Montironi, Shaobo Zhang

Research output: Contribution to journalArticle

64 Citations (Scopus)

Abstract

Bladder cancer is associated with high recurrence and mortality rates. These tumors show vast heterogeneity reflected by diverse morphologic manifestations and various molecular alterations associated with these disease phenotypes. Biomarkers that prospectively evaluate disease aggressiveness, progression risk, probability of recurrence and overall prognosis would improve patient care. Integration of molecular markers with conventional pathologic staging of bladder cancers may refine clinical decision making for the selection of adjuvant and salvage therapy. In the past decade, numerous bladder cancer biomarkers have been identified, including various tumor suppressor genes, oncogenes, growth factors, growth factor receptors, hormone receptors, proliferation and apoptosis markers, cell adhesion molecules, stromal factors, and oncoproteins. Recognition of two distinct pathways for urothelial carcinogenesis represents a major advance in the understanding and management of this disease. Nomograms for combining results from multiple biomarkers have been proposed to increase the accuracy of clinical predictions. The scope of this review is to summarize the major biomarker findings that may have translational and clinical implications.

Original languageEnglish
Pages (from-to)73-111
Number of pages39
JournalCritical Reviews in Oncology/Hematology
Volume89
Issue number1
DOIs
StatePublished - Jan 2014

Fingerprint

Urinary Bladder Neoplasms
Biomarkers
Recurrence
Salvage Therapy
Nomograms
Growth Factor Receptors
Oncogene Proteins
Cell Adhesion Molecules
Tumor Biomarkers
Disease Management
Tumor Suppressor Genes
Oncogenes
Disease Progression
Intercellular Signaling Peptides and Proteins
Patient Care
Carcinogenesis
Hormones
Apoptosis
Phenotype
Mortality

Keywords

  • Biomarkers
  • Prognosis
  • Tumorigenesis
  • Urinary bladder
  • Urothelial carcinoma

ASJC Scopus subject areas

  • Oncology
  • Hematology
  • Geriatrics and Gerontology

Cite this

Biomarkers in bladder cancer : Translational and clinical implications. / Cheng, Liang; Davison, Darrell D.; Adams, Julia; Lopez-Beltran, Antonio; Wang, Lisha; Montironi, Rodolfo; Zhang, Shaobo.

In: Critical Reviews in Oncology/Hematology, Vol. 89, No. 1, 01.2014, p. 73-111.

Research output: Contribution to journalArticle

Cheng, Liang ; Davison, Darrell D. ; Adams, Julia ; Lopez-Beltran, Antonio ; Wang, Lisha ; Montironi, Rodolfo ; Zhang, Shaobo. / Biomarkers in bladder cancer : Translational and clinical implications. In: Critical Reviews in Oncology/Hematology. 2014 ; Vol. 89, No. 1. pp. 73-111.
@article{482f02ec81b842a094dc0f0f4770e176,
title = "Biomarkers in bladder cancer: Translational and clinical implications",
abstract = "Bladder cancer is associated with high recurrence and mortality rates. These tumors show vast heterogeneity reflected by diverse morphologic manifestations and various molecular alterations associated with these disease phenotypes. Biomarkers that prospectively evaluate disease aggressiveness, progression risk, probability of recurrence and overall prognosis would improve patient care. Integration of molecular markers with conventional pathologic staging of bladder cancers may refine clinical decision making for the selection of adjuvant and salvage therapy. In the past decade, numerous bladder cancer biomarkers have been identified, including various tumor suppressor genes, oncogenes, growth factors, growth factor receptors, hormone receptors, proliferation and apoptosis markers, cell adhesion molecules, stromal factors, and oncoproteins. Recognition of two distinct pathways for urothelial carcinogenesis represents a major advance in the understanding and management of this disease. Nomograms for combining results from multiple biomarkers have been proposed to increase the accuracy of clinical predictions. The scope of this review is to summarize the major biomarker findings that may have translational and clinical implications.",
keywords = "Biomarkers, Prognosis, Tumorigenesis, Urinary bladder, Urothelial carcinoma",
author = "Liang Cheng and Davison, {Darrell D.} and Julia Adams and Antonio Lopez-Beltran and Lisha Wang and Rodolfo Montironi and Shaobo Zhang",
year = "2014",
month = "1",
doi = "10.1016/j.critrevonc.2013.08.008",
language = "English",
volume = "89",
pages = "73--111",
journal = "Critical Reviews in Oncology/Hematology",
issn = "1040-8428",
publisher = "Elsevier Ireland Ltd",
number = "1",

}

TY - JOUR

T1 - Biomarkers in bladder cancer

T2 - Translational and clinical implications

AU - Cheng, Liang

AU - Davison, Darrell D.

AU - Adams, Julia

AU - Lopez-Beltran, Antonio

AU - Wang, Lisha

AU - Montironi, Rodolfo

AU - Zhang, Shaobo

PY - 2014/1

Y1 - 2014/1

N2 - Bladder cancer is associated with high recurrence and mortality rates. These tumors show vast heterogeneity reflected by diverse morphologic manifestations and various molecular alterations associated with these disease phenotypes. Biomarkers that prospectively evaluate disease aggressiveness, progression risk, probability of recurrence and overall prognosis would improve patient care. Integration of molecular markers with conventional pathologic staging of bladder cancers may refine clinical decision making for the selection of adjuvant and salvage therapy. In the past decade, numerous bladder cancer biomarkers have been identified, including various tumor suppressor genes, oncogenes, growth factors, growth factor receptors, hormone receptors, proliferation and apoptosis markers, cell adhesion molecules, stromal factors, and oncoproteins. Recognition of two distinct pathways for urothelial carcinogenesis represents a major advance in the understanding and management of this disease. Nomograms for combining results from multiple biomarkers have been proposed to increase the accuracy of clinical predictions. The scope of this review is to summarize the major biomarker findings that may have translational and clinical implications.

AB - Bladder cancer is associated with high recurrence and mortality rates. These tumors show vast heterogeneity reflected by diverse morphologic manifestations and various molecular alterations associated with these disease phenotypes. Biomarkers that prospectively evaluate disease aggressiveness, progression risk, probability of recurrence and overall prognosis would improve patient care. Integration of molecular markers with conventional pathologic staging of bladder cancers may refine clinical decision making for the selection of adjuvant and salvage therapy. In the past decade, numerous bladder cancer biomarkers have been identified, including various tumor suppressor genes, oncogenes, growth factors, growth factor receptors, hormone receptors, proliferation and apoptosis markers, cell adhesion molecules, stromal factors, and oncoproteins. Recognition of two distinct pathways for urothelial carcinogenesis represents a major advance in the understanding and management of this disease. Nomograms for combining results from multiple biomarkers have been proposed to increase the accuracy of clinical predictions. The scope of this review is to summarize the major biomarker findings that may have translational and clinical implications.

KW - Biomarkers

KW - Prognosis

KW - Tumorigenesis

KW - Urinary bladder

KW - Urothelial carcinoma

UR - http://www.scopus.com/inward/record.url?scp=84890878317&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84890878317&partnerID=8YFLogxK

U2 - 10.1016/j.critrevonc.2013.08.008

DO - 10.1016/j.critrevonc.2013.08.008

M3 - Article

C2 - 24029603

AN - SCOPUS:84890878317

VL - 89

SP - 73

EP - 111

JO - Critical Reviews in Oncology/Hematology

JF - Critical Reviews in Oncology/Hematology

SN - 1040-8428

IS - 1

ER -